Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 127Neoplasm Metastasis 14Neoplasms 9Advanced Breast Cancer 6Endometrial Neoplasms 5Recurrence 4Hereditary Sensory and Autonomic Neuropathies 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Squamous Cell Carcinoma of Head and Neck 2Polycystic Ovary Syndrome 2Osteoporosis 2Neoplasms by Site 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Breast Neoplasms, Male 2Breast Diseases 2Bone Diseases, Metabolic 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1Osteitis Deformans 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × Letrozole × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡